Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Abciximab in Angioplasty

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Advances in percutaneous coronary intervention (PCI) have allowed procedures to be performed on a variety of patients with a spectrum of challenging coronary anatomy. Abciximab has permitted further expansion and has made the procedure safer. Abciximab is a chimerised murine monoclonal antibody directed against the platelet glycoprotein (GP) IIb–IIIa receptor. Binding to this receptor inhibits platelet aggregation to a wide variety of biological agonists. It also binds to αvβ3 and leucocyte MAC-1 receptors; the biological significance of its affinity to these receptors is unclear. Abciximab has an extremely short plasma half-life. Since abciximab binds to the platelet GP IIb–IIIa receptor with great avidity it has an extremely long biological half-life.

The use of abciximab is currently confined primarily to PCIs. The first large trial, EPIC, established that abciximab, given with aspirin (acetylsalicylic acid) and heparin, reduced the frequency of peri-procedural ischaemic events by 35% in high-risk patients. For this reduction a bolus of 0.25 mg/kg was followed by a 12-hour infusion of abciximab. However, the transfusion rate was doubled. A subsequent trial, EPILOG, indicated that reduction of the dose of heparin along with expeditious removal of arterial access sheaths, reduced the rate of haemorrhagic complications to a level comparable with placebo-treated patients, while also amplifying the reduction in ischaemic events.

In a third trial, EPISTENT, this benefit was shown to include patients undergoing elective coronary stent implantation. Additional trials have demonstrated that the same effect is present in patients undergoing primary PCI for acute myocardial infarction and in patients undergoing PCI for refractory unstable angina pectoris. In the latter situation, treatment with abciximab for 18 to 24 hours preceding the intervention reduced the rate of myocardial infarction even before the procedure was begun.

The rationale for the use abciximab is thus clearly established. Bleeding complications can be reduced by limiting the heparin dose, avoiding unneeded venous access site punctures, and expeditious removal of arterial sheaths. In emergency coronary artery bypass surgery, platelet transfusion reduces the number of receptors occupied per platelet and is likely to reduce the degree of postoperative bleeding.

The cost of abciximab remains an issue; however, this is partially offset by the reduction in ischaemic complications and accompanying resource use. In patients undergoing elective coronary stenting, abciximab use reduced the long term rate of target vessel revascularisation. The degree to which this reduction results in further cost savings will require further analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61–8

    Article  PubMed  CAS  Google Scholar 

  2. Leon, MB, Baim DS, Gordon P, et al. Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS) [abstract]. Circulation 1998; 94 Suppl. I: I–165

    Google Scholar 

  3. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528–36

    Article  PubMed  CAS  Google Scholar 

  4. Kong TQ, Davidson CJ, Meyers SN, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions JAMA 1997; 277: 461–6

    Article  PubMed  CAS  Google Scholar 

  5. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739–50

    Article  PubMed  CAS  Google Scholar 

  6. Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966; 48: 19–44

    PubMed  CAS  Google Scholar 

  7. Plow EF, McEver RP, Coller BS, et al. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724–7

    PubMed  CAS  Google Scholar 

  8. Weiss HJ, Turitto VT, Baumgartner HR. Further evidence that glycoprotein IIb–IIIa mediates platelet spreading on sub-endothelium. Thromb Haemost 1991; 65: 202–5

    PubMed  CAS  Google Scholar 

  9. Weiss HJ, Hawiger J, Ruggeri ZM, et al. Fibrinogen-independent platelet adhesion and thrombus formation on sub-endothelium mediated by glycoprotein IIb–IIIa complex at high shear rate. J Clin Invest 1989; 83: 288–97

    Article  PubMed  CAS  Google Scholar 

  10. Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907–14

    PubMed  CAS  Google Scholar 

  11. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101–8

    Article  PubMed  CAS  Google Scholar 

  12. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757–64

    Article  PubMed  CAS  Google Scholar 

  13. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863–74

    Article  PubMed  CAS  Google Scholar 

  14. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly: kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988; 263: 3823–34

    PubMed  CAS  Google Scholar 

  15. Tam SH, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIB/IIIA and αvβ3 integrins. Circulation 1998; 98: 1085–91

    Article  PubMed  CAS  Google Scholar 

  16. Simon DI, Xu H, Ortlepp, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leucocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528–35

    Article  PubMed  CAS  Google Scholar 

  17. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670–7

    Article  PubMed  CAS  Google Scholar 

  18. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb–IIIa interactions with integrilin: enhanced GP IIb–IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anti-coagulated with citrate. Circulation 1997; 96: 1488–94

    Article  PubMed  CAS  Google Scholar 

  19. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention — IMPACT-II. Lancet 1997; 349: 1422–8

    Article  Google Scholar 

  20. Blankenship JC, Sigmon KN, Tardiff BE, et al. Effect of glycoprotein iib/iiia receptor inhibition on specific in-lab complications of coronary intervention and resultant CKMB elevation in the IMPACT II trial [abstract]. Circulation 1996; 94: I–198

    Google Scholar 

  21. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665–71

    Article  PubMed  CAS  Google Scholar 

  22. Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995; 91: 1427–31

    Article  PubMed  CAS  Google Scholar 

  23. Mascelli MA, Lance ET, Wagner CL, et al. Abciximab [7E3] pharmacodynamics demonstrate an extended and gradual recovery from GP Ib/IIIa blockade [abstract]. Circulation 1996; 96: I–513

    Google Scholar 

  24. Kereiakes DJ. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery [abstract]. Am J Cardiol 1998; 81: 373

    Article  PubMed  CAS  Google Scholar 

  25. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61

    Article  Google Scholar 

  26. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882–90

    Article  PubMed  CAS  Google Scholar 

  27. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559–62

    Article  PubMed  CAS  Google Scholar 

  28. The EPILOG Investigators. Platelet glycoprotein IIB/IIIA receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–96

    Article  Google Scholar 

  29. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina — the CAPTURE Study. Lancet 1997; 349: 1429–35

    Article  Google Scholar 

  30. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randominsed Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–41

    Article  PubMed  CAS  Google Scholar 

  31. The EPISTENT Study Group. Randomised placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIB/IIIA blockade. Lancet 1998; 352: 87–92

    Google Scholar 

  32. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 1434–5

    Article  Google Scholar 

  33. Schwartz RS, Holmes DRJ, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284–93

    Article  PubMed  CAS  Google Scholar 

  34. Topol EJ, Ferguson JJ, Weisman HF, et al. on behalf of the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479–84

    Article  PubMed  CAS  Google Scholar 

  35. Le Breton H, Rabbani R, Moussa S, et al. The role of integrins αIIbβ3 (glycoprotein IIb/IIIa) and αvβ3 (the vitronectin receptor) in a guinea pig model of restenosis [abstract]. Circulation 1997; 94: I–517

    Google Scholar 

  36. Stromblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462–8

    Article  PubMed  CAS  Google Scholar 

  37. Ellis SG, Serruys, Popma JJ, et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results [abstract]. Circulation 1997; 96 Suppl.: 87

    Google Scholar 

  38. Husten L. Regimen lowers rate of coronary events in diabetes. Lancet 1998; 352: 711

    Article  PubMed  CAS  Google Scholar 

  39. Lincoff AM, Tcheng JE, Califf RM, et al. on behalf of the PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997; 79: 286–91

    Article  PubMed  CAS  Google Scholar 

  40. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 fab (abciximab) therapy. Circulation 1997; 95: 809–13

    Article  PubMed  CAS  Google Scholar 

  41. Madan M, Kereiakes DJ, Rund MM, et al. Abciximab readministration for coronary interventions: is it safe? [abstract]. Circulation 1997; 96: I–901

    Google Scholar 

  42. Tcheng JE, Kereiakes DJ, George G, et al. Safety of readministration of abciximab; interim results of the reopro readministration registry R3 [abstract]. J Am Coll Cardiol 1998; 31: 55A

    Article  Google Scholar 

  43. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629–35

    Article  PubMed  CAS  Google Scholar 

  44. Lincoff AM, Mark DB, Califf RM, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG Trial [abstract]. J Am Coll Cardiol 1997; 29: 240A

    Article  Google Scholar 

  45. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995; 25: 1693–9

    Article  PubMed  CAS  Google Scholar 

  46. Bowman A, Young S. Graphical comparison of nonparametric curves. Appl Stat 1997; 45: 83–98

    Article  Google Scholar 

  47. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus. Semin Thromb Hemost 1991; 17: 422–5

    Article  PubMed  CAS  Google Scholar 

  48. Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998; 97: 322–31

    Article  PubMed  CAS  Google Scholar 

  49. Lefkovits J, Blankenship JC, Anderson KM, et al. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial: evaluation of c7E3 for the prevention of ischemic complications. J Am Coll Cardiol 1996; 28: 849–55

    Article  PubMed  CAS  Google Scholar 

  50. Ghaffari S, Kereiakes DJ, Kelly T, et al. Platelet GP IIb/IIIa receptor blockade reduces ischemic complications in patients undergoing directional coronary atherectomy [abstract]. Circulation 1996; 94: I–198

    Google Scholar 

  51. Bass T, Williams DO, Ho KK, et al. Is an aggressive rotablator strategy preferable to a standard rotoblator strategy in patients with heavily calcified lesions?: a report from the STRATAS trial [abstract]. J Am Coll Cardiol 1998; 31: 378A

    Article  Google Scholar 

  52. Williams MS, Coller BS, Vaananen HJ, et al. Activation of platelets in platelet-rich plasma by rotablation is speed dependent and can be inhibited by Abciximab (c7E3 Fab, ReoPro™) [abstract]. J Am Coll Cardiol 1998; 31: 237A

    Article  Google Scholar 

  53. Rawitscher D, Levin TN, Cohen I, et al. Rapid reversal of noreflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 42: 187–90

    Article  PubMed  CAS  Google Scholar 

  54. Braden GA, Love WM, Appelgate RJ, et al. Abciximab decreases the incidence and magnitude of non-Q-wave myocardial infarction associated with rotational atherectomy [abstract]. J Am Coll Cardiol 1998; 31: 237A

    Article  Google Scholar 

  55. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96: 1761–9

    Article  Google Scholar 

  56. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia — a serial intravascular ultrasound study. Circulation 1997; 95: 1366–9

    Article  PubMed  CAS  Google Scholar 

  57. Vanbelle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients — a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454–60

    Article  CAS  Google Scholar 

  58. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74

    Article  PubMed  CAS  Google Scholar 

  59. Davi G, Gennaro F, Spatola A, et al. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications 1992; 6: 7–11

    Article  PubMed  CAS  Google Scholar 

  60. Kleiman NS, Lincoff AM, Kereiaaakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade and heparin: evidence for a complex interaction in a multicenter trial. Circulation 1998; 97: 1912–20

    Article  PubMed  CAS  Google Scholar 

  61. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIB/IIIA receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045–51

    Article  PubMed  CAS  Google Scholar 

  62. Khan MM, Ellis SG, Aguirre FV, et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty — clinical and angiographic outcomes in a large multicenter trial. J Am Coll Cardiol 1998; 31: 31–6

    Article  PubMed  CAS  Google Scholar 

  63. Muhlestein JB, Karagounis LA, Treehan S, et al. ’Rescue’ utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30: 1729–34

    Article  PubMed  CAS  Google Scholar 

  64. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105–12

    Article  PubMed  CAS  Google Scholar 

  65. Kereiakes DJ, Broderick TM, Whang DD, et al. Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Am J Cardiol 1997; 80: 633–4

    Article  PubMed  CAS  Google Scholar 

  66. The PRISM PLUS Study Group. Inhibition of the platelet glycoprotein IIb/IIa receptor tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischaemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. New Engl J Med 1998; 338: 1488–97

    Article  Google Scholar 

  67. The PRISM PLUS Study Group. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischaemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. New Engl J Med 1998; 338: 1498–1505

    Article  Google Scholar 

  68. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Eng J Med 1998; 339: 436–43

    Article  Google Scholar 

  69. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291–8

    Article  PubMed  CAS  Google Scholar 

  70. Kleiman NS, Mascelli MA, Graziedei N, et al. Ticlopidine potentiates abciximab’s ability to inhibit ADP-induced platelet aggregation in vitro [abstract]. J Am Coll Cardiol 1997; 29: 241A

    Google Scholar 

  71. Kleiman NS, Graziedei N, Lance E, et al. Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting [abstract]. J Am Coll Cardiol 1998; 31: 238A

    Article  Google Scholar 

  72. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab administration for complex coronary intervention. Circulation 1996; 94: 906–10

    Article  PubMed  CAS  Google Scholar 

  73. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety and outcomes following prolonged platelet glycoprotein IIb/IIIa receptor blockade with xemilofiban: results of a multicenter placebo controlled randomized trial. Circulation 1998; 98: 1268–78

    Article  PubMed  CAS  Google Scholar 

  74. Boehrer JD, Kereiakes DJ, Navetta FI, et al. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994; 74: 1166–70

    Article  PubMed  CAS  Google Scholar 

  75. Lincoff AM, Topol EJ, Califf RM, et al. Influence of platelet GP IIb/IIIa receptor inhibition with c7E3 on the sequelae of dissection during percutaneous transluminal coronary intervention [abstract]. J Am Coll Cardiol 1995; 390A

  76. Gammie JS, Zenati M, Kormos, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998; 65: 465–9

    Article  PubMed  CAS  Google Scholar 

  77. Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107–17

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, The Methodist Hospital, 6565 Fannin Street, MS F1090, Houston, Texas, TX 77030, USA

    Neal S. Kleiman

Authors
  1. Neal S. Kleiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal S. Kleiman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleiman, N.S. A Risk-Benefit Assessment of Abciximab in Angioplasty. Drug-Safety 20, 43–57 (1999). https://doi.org/10.2165/00002018-199920010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920010-00005

Keywords

Search

Navigation